A HIV Vaccine Targeting Protease Cleavage Sites

针对蛋白酶裂解位点的 HIV 疫苗

• 批准号: 286287
• 负责人: Luo Ma
• 金额: $ 7.29万
• 依托单位: University of Manitoba
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-03-01 至 2014-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=286287&lang=en
• 关键词: A Hiv Vaccine Tarting Protease Cleavage Sites; Low Dose Vaginal Sivmac251 Challenge; Mice And Guinea Pigs; Nanodelivery Of Immunogens; Nonhuman Primate And Sivmac239/251 Model; Vesicular Stomatitis Virus (Vsv) Vector System

Currently, >25 million people have died of HIV/AIDS and 34 million are living with HIV/AIDS in the world. Medications have improved the quality of life and life expectancy of HIV-infected. However, for each person getting treatment, 2 or 3 become newly in

目前，全世界有超过2 500万人死于艾滋病毒/艾滋病，3 400万人感染艾滋病毒/艾滋病。药物改善了艾滋病毒感染者的生活质量和预期寿命。然而，对于每一个接受治疗的人来说，